Clinical follow-up on the development of impulse control disorders in Parkinson's disease

Clinical follow-up on the development of impulse control disorders in Parkinson's disease - Follow-up ICD in PD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47691

Enrollment

Registered

2014-07-16

Start date

2014-09-23

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

impulsscontrolestoornissen shaking palsy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: medication-naive (de novo) Parkinson's disease patients who underwent a dopamine transporter SPECT scan and MRI scan at baseline in the VU University medical center.

Exclusion criteria

Exclusion criteria: use of medication at baseline that influences DaT tracer binding (including serotonin reuptake inhibitors).

Design outcomes

Primary

Measure	Time frame
- Striatal dopamine transporter availability (measured with DaT SPECT) at baseline - presence and severity of symptoms of impulse control disorders at baseline and follow-up	—

Secondary

Measure	Time frame
- course of the symptoms of depression, anxiety, impulsivity and executive functioning with progression of the disease and possible effects of treatment. - temporal relation between the symptoms of depression, anxiety, impulsivity and cognitive functioning.	—

Countries

Netherlands

Outcome results